HMGN (Hemagen Diagnostics) Research & Development: $0.04 Mil (TTM As of Sep. 2012)


What is Hemagen Diagnostics Research & Development?

Hemagen Diagnostics HMGN +766.67% Research & Development is $0.04 Mil as of Sep. 2012.

Research & Development is the aggregate amount of research and development expenses during the year. Hemagen Diagnostics's Research & Development for the three months ended in Sep. 2012 was $0.02 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Sep. 2012 was $0.04 Mil.

Hemagen Diagnostics  (OTCPK:HMGN) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Hemagen Diagnostics Research & Development Related Terms

Hemagen Diagnostics Research & Development Historical Data

* Premium members only.

The historical data trend for Hemagen Diagnostics's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hemagen Diagnostics Research & Development Chart

Hemagen Diagnostics Annual Data
Trend Sep03 Sep04 Sep05 Sep06 Sep07 Sep08 Sep09 Sep10 Sep11 Sep12
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.15 0.09 0.03 0.01 0.05

Hemagen Diagnostics Quarterly Data
Dec07 Mar08 Jun08 Sep08 Dec08 Mar09 Jun09 Sep09 Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.03 0.00 0.02

Hemagen Diagnostics Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Sep. 2012 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.04 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $0.04 Mil mean?
Hemagen Diagnostics (HMGN) has a Research & Development of $0.04 Mil as of Sep. 2012. Research and development expense is the total cost for research and development activities. View historical data on Hemagen Diagnostics and its competitors.
Is Hemagen Diagnostics' Research & Development too high?
Hemagen Diagnostics' current Research & Development is $0.04 Mil.
How does Hemagen Diagnostics' Research & Development compare to OBMP and NSPX?
Hemagen Diagnostics' Research & Development of $0.04 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Hemagen Diagnostics and its competitors. Hemagen Diagnostics's current Research & Development is $0.04 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hemagen Diagnostics stock overvalued right now?
Hemagen Diagnostics (HMGN) has a current Research & Development of $0.04 Mil. The current Research & Development is $0.04 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Hemagen Diagnostics (HMGN), the current Research & Development is $0.04 Mil as of Sep. 2012. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Hemagen Diagnostics Business Description

Address 9033 Red Branch Road, Columbia, MD, USA, 21045
Hemagen Diagnostics Inc is a biotechnology company. It develops, manufactures and markets Food and Drug Administration cleared proprietary medical diagnostic test kits and components. The company's Virgo line of Immunoassays are used to aid in the diagnosis of autoimmune and infectious diseases and acute-phase proteins. The assays utilize multiple technologies including ELISA, immunofluorescence (IFA) and hemagglutination (HA). Its products include ANA Screen ELISA 96 Test System, Rubella IgG ELISA 96 Test System, AMA IFA 48 Test System and others.